Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Liljeroos to Advise Modulight Board of Directors
Apr 2017
TAMPERE, Finland, April 17, 2017 — Biomedical laser manufacturer Modulight Inc. has appointed Jyrki Liljeroos as a senior advisor to its board of directors.

Liljeroos to Advise Modulight Board of DirectorsLiljeroos brings experience in the pharmaceutical and health care industries. He was the CEO and executive chairman of Santen Oy for 20 years.

“I am truly excited about Jyrki starting to work with us,” said Seppo Orsila, executive chairman of Modulight. “Having known him for some time, I know his advice and guidance has already helped us forward. We all expect to both benefit and enjoy working with him. Jyrki’s experience in international business and pharmaceutical industry provides us an excellent match to our strategy as we continue the rapid growth of Modulight.”

Modulight develops biomedical lasers for genetics, oncology and ophthalmology.

“I have been admiring over the years how Modulight has emerged in the medical applications market and created biomedical lasers for applications like oncology, surgery and biomedical illumination,” Liljeroos said. “Combining medical high-tech innovations with pharmaceuticals will bring added value to the patients and health care. Already premarket approved and delivering to seven pharmas in the U.S., Modulight has significant potential of growing in the field of medical business internationally. I'm enthusiastic to join Modulight's board of directors and contribute to the strategic decisions with my experience and knowledge.”

BusinesslasersBiophotonicsModulightJyrki LiljeroosEurope

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.